Shares of NeoGenomics, Inc. (NASDAQ:NEO) have been given an average recommendation of “Buy” by the ten brokerages that are currently covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $16.80.
Several equities research analysts have issued reports on NEO shares. Scotiabank set a $22.00 price target on shares of NeoGenomics and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Janney Montgomery Scott restated a “buy” rating on shares of NeoGenomics in a research note on Thursday, October 26th. Zacks Investment Research upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a research note on Friday. BidaskClub upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a research note on Monday, February 5th. Finally, CIBC set a $19.00 price objective on shares of NeoGenomics and gave the stock a “neutral” rating in a research note on Wednesday, January 3rd.
Shares of NeoGenomics (NASDAQ NEO) traded up $0.17 during mid-day trading on Tuesday, reaching $8.25. 674,800 shares of the company’s stock traded hands, compared to its average volume of 435,996. The company has a quick ratio of 1.99, a current ratio of 2.14 and a debt-to-equity ratio of 0.57. NeoGenomics has a 12-month low of $7.08 and a 12-month high of $11.63. The firm has a market cap of $649.71, a price-to-earnings ratio of -58.92, a P/E/G ratio of 3.26 and a beta of 0.57.
NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Wednesday, February 21st. The medical research company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.02. NeoGenomics had a negative net margin of 1.37% and a positive return on equity of 4.37%. The firm had revenue of $67.79 million for the quarter, compared to analyst estimates of $66.32 million. During the same period in the previous year, the business earned $0.05 EPS. The company’s revenue was up 12.1% compared to the same quarter last year. equities analysts expect that NeoGenomics will post 0.12 earnings per share for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in NEO. Schwab Charles Investment Management Inc. increased its stake in shares of NeoGenomics by 0.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 199,654 shares of the medical research company’s stock worth $1,789,000 after purchasing an additional 1,235 shares during the last quarter. Alliancebernstein L.P. increased its stake in shares of NeoGenomics by 34.6% during the 2nd quarter. Alliancebernstein L.P. now owns 45,500 shares of the medical research company’s stock worth $408,000 after purchasing an additional 11,700 shares during the last quarter. Teachers Advisors LLC boosted its holdings in shares of NeoGenomics by 6.0% during the 2nd quarter. Teachers Advisors LLC now owns 101,926 shares of the medical research company’s stock worth $913,000 after buying an additional 5,758 shares during the period. TIAA CREF Investment Management LLC boosted its holdings in shares of NeoGenomics by 0.4% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 149,220 shares of the medical research company’s stock worth $1,337,000 after buying an additional 581 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of NeoGenomics by 10.6% during the 2nd quarter. Northern Trust Corp now owns 979,841 shares of the medical research company’s stock worth $8,780,000 after buying an additional 94,277 shares during the period. Institutional investors own 83.24% of the company’s stock.
WARNING: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/23/brokerages-set-neogenomics-inc-neo-price-target-at-16-80.html.
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.